Publications by authors named "Yeşim Uygun Kizmaz"

4 Publications

  • Page 1 of 1

COVID-19 presenting with diarrhea in a heart transplant patient.

Turk Gogus Kalp Damar Cerrahisi Derg 2021 Jan 13;29(1):119-121. Epub 2021 Jan 13.

Department of Cardiovascular Surgery, Koşuyolu Yüksek Ihtisas Training and Research Hospital, Istanbul, Turkey.

A 55-year-old man who underwent bicaval orthotopic heart transplantation nine months earlier presented with complaints of diarrhea and oliguria. Laboratory findings showed pancytopenia and an elevated creatinine level. Cyclosporine and mycophenolate mofetil were discontinued, and the patient received only everolimus. As he was immunosuppressed and had atypical symptoms during the COVID-19 pandemic, reverse transcriptase-polymerase chain reaction testing was performed, which yielded a positive result. Treatment with hydroxychloroquine and favipiravir were initiated. Although the patient suffered from acute renal failure, his condition showed an improvement after hydration plus a five-day antiviral treatment and, then, treatment was stopped. His COVID-19 test was negative after 10 days of follow-up and treatment, and he was discharged with cyclosporin and mycophenolate mofetil.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.5606/tgkdc.dergisi.2021.20420DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7970087PMC
January 2021

Lung Transplantation for Cystic Fibrosis in Turkey: First Report.

Exp Clin Transplant 2021 Feb 17. Epub 2021 Feb 17.

From the Department of Thoracic Surgery, Kartal Kosuyolu Training and Research Hospital, Istanbul, Turkey.

Objectives: Lung transplant is the most important treatment approach that improves the life expectancy and quality of life for patients with cystic fibrosis with end-stage lung disease. In this study, we retros-pectively analyzed patients with cystic fibrosis who were referred to our lung transplant program in Turkey.

Materials And Methods: We evaluated 14 patients with cystic fibrosis who were referred to our lung transplant clinic between December 2016 and December 2019. The characteristics of the patients at the time of referral to our lung transplant clinic, survival, and lung transplant results were recorded.

Results: Four patients died on the wait list, 3 patients were not eligible for lung transplant, and lung transplant was performed in 7 patients. The mean age of all patients was 22.8 years (range, 11-41 years), and the mean age for patients who underwent lung transplant was 27.5 years (range, 21-41 years). The mean time of suitable donor offer or survival life was 140 days in the patients who were referred for lung transplant. The 1-year mortality rate was 28.6% (2 of 7 patients) after lung transplant. One patient died of chronic lung allograft dysfunction at the 25th month after lung transplant. Four patients were alive without any problems.

Conclusions: Lung transplant is the final treatment method for patients with cystic fibrosis with terminal period lung disease. To provide the best benefit, patients should be evaluated for transplant early. Cystic fibrosis care clinics and lung transplant clinics should work in coordination in order to increase the number of lung transplants and improve outcomes.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.6002/ect.2020.0282DOI Listing
February 2021

Consensus Report on Diagnosis, Treatment and Prevention of Infective Endocarditis by Turkish Society of Cardiovascular Surgery (TSCVS), Turkish Society of Clinical Microbiology and Infectious Diseases (KLIMIK), Turkish Society of Cardiology (TSC), Turkish Society of Nuclear Medicine (TSNM), Turkish Society of Radiology (TSR), Turkish Dental Association (TDA) and Federation of Turkish Pathology Societies (TURKPATH) Cardiovascular System Study Group.

Turk Gogus Kalp Damar Cerrahisi Derg 2020 Jan 23;28(1):2-42. Epub 2020 Jan 23.

Infective Endocarditis and Other Cardiovascular Infections Study Group.

Infective endocarditis (IE) is rare, but associated with significant morbidity and mortality rates. Estimates of the incidence of IE in Turkey are compromised by the absence of population-based prospective studies. Due to the frequent presence of predisposing cardiac conditions and higher rates of nosocomial bacteremia in highrisk groups, the incidence of IE is expected to be higher in Turkey. Additionally, while IE generally affects older people in developed countries, it still affects young people in Turkey. In order to reduce the mortality and morbidity, it is critical to diagnose the IE to determine the causative agent and to start treatment rapidly. However, most of the patients cannot be diagnosed in their first visits, about half of them can be diagnosed after three months, and the disease often goes unnoticed. In patients diagnosed with IE, the rate of identification of causative organisms is significantly lower in Turkey than in developed countries. Furthermore, most of the centers do not perform some essential microbiological diagnostic tests as a routine practice. Some antimicrobials that are recommended as the first-line of treatment for IE, particularly antistaphylococcal penicillins, are not available in Turkey. These problems necessitate reviewing the epidemiological, laboratory, and clinical characteristics of IE in our country, as well as the current information about its diagnosis, treatment, and prevention together with local data. Physicians can follow patients with IE in many specialties. Diagnosis and treatment processes of IE should be standardized at every stage so that management of IE, a setting in which many physicians are involved, can always be in line with current recommendations. Study Group for Infective Endocarditis and Other Cardiovascular Infections of the Turkish Society of Clinical Microbiology and Infectious Diseases has called for collaboration of the relevant specialist organizations to establish a consensus report on the diagnosis, treatment, and prevention of IE in the light of current information and local data in Turkey.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.5606/tgkdc.dergisi.2020.01954DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7067027PMC
January 2020

Diagnosis, treatment and prevention of infective endocarditis: Turkish consensus report-2019.

Turk Kardiyol Dern Ars 2020 03;48(2):187-226

Turkish Society of Clinical Microbiology and Infectious Diseases, Infective Endocarditis and Other Cardiovascular Infections Study Grup (Istanbul University, Dr. Siyami Ersek Thoracic and Cardiovascular Surgery Training and Resarch Hospital, Başkent University, İstanbul Medeniyet University, Ankara University, Kartal Koşuyolu High Speciality Training and Research Hospital, Kırşehir Ahi Evran University, Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, Bezmiâlem Vakıf University, Mehmet Akif Ersoy Thoracic and Cardiovascular Surgery Training and Resarch Hospital, Ankara City Hospital, Marmara University, Uludağ University, Yozgat Bozok University, Göztepe Training and Research Hospital), İstanbul, Turkey.

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.5543/tkda.2020.89689DOI Listing
March 2020